Literature DB >> 10360661

Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.

D S Liscia1, R Morizio, T Venesio, C Palenzona, M Donadio, R Callahan.   

Abstract

Several studies indicate that the short arm of chromosome 17 is one of the most frequently altered regions in sporadic breast carcinomas (45-60%). In the present report the 17p13.3-ter locus in tumour DNA of breast cancer patients, along with their matching normal lymphocyte DNA, have been mapped with four markers (D17S5, D17S379, ABR and D17S34), spanning nearly 3 cM of the telomer. Sixty-five of 143 heterozygous tumours had lost at least one of the markers at the minimum region of loss (45%). High levels of loss of these distal markers on 17p13.3 are independent of TP53 mutations and are associated with tumour cell proliferation. A follow-up period of over 7 years demonstrates that loss of these markers correlates both with disease-free (P = 0.004) and overall survival (P = 0.007). In addition we show that for disease-free survival the prognostic power of this genetic alteration is second only to axillary lymph node involvement (3.1 vs 6.3 relative risk), and is a better predictor than the mutational status of TP53 (1.6 relative risk). Our results are further evidence of the presence, within the region, of at least a second tumour suppressor gene distal to TP53, that might be targeted by deletions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360661      PMCID: PMC2362303          DOI: 10.1038/sj.bjc.6690427

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

Authors:  J Milner; E A Medcalf
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

2.  A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology?

Authors:  I Mittra; K D MacRae
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Hereditary cancer, oncogenes, and antioncogenes.

Authors:  A G Knudson
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

4.  Inherited p53 gene mutations in breast cancer.

Authors:  D Sidransky; T Tokino; K Helzlsouer; B Zehnbauer; G Rausch; B Shelton; L Prestigiacomo; B Vogelstein; N Davidson
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

5.  Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p13.3).

Authors:  R Carrozzo; D H Ledbetter
Journal:  Hum Mol Genet       Date:  1993-05       Impact factor: 6.150

6.  Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer.

Authors:  G Bonadonna; P Valagussa; G Tancini; A Rossi; C Brambilla; M Zambetti; P Bignami; G Di Fronzo; R Silvestrini
Journal:  NCI Monogr       Date:  1986

7.  Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas.

Authors:  A Lindblom; L Skoog; T I Andersen; S Rotstein; M Nordenskjöld; C Larsson
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

8.  Human ABR encodes a protein with GAPrac activity and homology to the DBL nucleotide exchange factor domain.

Authors:  N Heisterkamp; V Kaartinen; S van Soest; G M Bokoch; J Groffen
Journal:  J Biol Chem       Date:  1993-08-15       Impact factor: 5.157

9.  Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis.

Authors:  C Coles; A M Thompson; P A Elder; B B Cohen; I M Mackenzie; G Cranston; U Chetty; J Mackay; M Macdonald; Y Nakamura
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

10.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

View more
  7 in total

Review 1.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

2.  Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis.

Authors:  Chun-Ming Chen; Richard R Behringer
Journal:  Genes Dev       Date:  2004-01-26       Impact factor: 11.361

3.  Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.

Authors:  G Nicoll; D N Crichton; H E McDowell; N Kernohan; T R Hupp; A M Thompson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

4.  Loss of heterozygosity in the Hodgkin-Reed Sternberg cell line L1236.

Authors:  A Staratschek-Jox; R K Thomas; T Zander; N Massoudi; M Kornacker; J Bullerdiek; C Fonatsch; V Diehl; J Wolf
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

5.  ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia.

Authors:  Carolina Yaeko Namasu; Christiane Katzerke; Daniela Bräuer-Hartmann; Alexander Arthur Wurm; Dennis Gerloff; Jens-Uwe Hartmann; Sebastian Schwind; Carsten Müller-Tidow; Nadja Hilger; Stephan Fricke; Maximilian Christopeit; Dietger Niederwieser; Gerhard Behre
Journal:  Oncotarget       Date:  2017-10-26

6.  Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients.

Authors:  Mina Sharbatoghli; Fahimeh Fattahi; Hamidreza Aboulkheyr Es; Arvand Akbari; Setareh Akhavan; Marzieh Ebrahimi; Mohsen Asadi-Lari; Mehdi Totonchi; Zahra Madjd
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

7.  miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.

Authors:  Peng Ge; Lei Cao; Xin Chen; Ruijun Jing; Wanxia Yue
Journal:  BMC Cancer       Date:  2019-12-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.